ImmuPharma (LON:IMM) Shares Down 15.6% – Time to Sell?

ImmuPharma plc (LON:IMMGet Free Report) shares dropped 15.6% during trading on Wednesday . The stock traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.98 ($0.06). Approximately 68,204,375 shares changed hands during trading, an increase of 164% from the average daily volume of 25,820,418 shares. The stock had previously closed at GBX 5.90 ($0.07).

ImmuPharma Trading Down 15.6 %

The firm has a market capitalization of £20.74 million, a P/E ratio of -498.00 and a beta of 1.53. The stock has a 50-day simple moving average of GBX 1.92 and a two-hundred day simple moving average of GBX 1.78.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

See Also

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.